Submit your email to push it up the queue
Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, is a leading biopharmaceutical company headquartered in the United States. Founded in 2009, it has rapidly established itself in the biotechnology industry, focusing on innovative treatments in areas such as immunology, oncology, and infectious diseases. With a commitment to advancing healthcare, Janssen Biotech is renowned for its core products, including biologics and targeted therapies that address complex medical conditions. The company’s unique approach to drug development and its robust pipeline have positioned it as a key player in the global market. Notable achievements include the successful launch of groundbreaking therapies that have transformed patient care, solidifying Janssen Biotech's reputation for excellence and innovation in the biopharmaceutical landscape.
How does Janssen Biotech, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Janssen Biotech, Inc.'s score of 78 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Janssen Biotech, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Johnson & Johnson, which influences its climate commitments and emissions reporting. As part of its corporate family, Janssen Biotech inherits climate initiatives and targets from Johnson & Johnson. This includes participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are aimed at reducing carbon emissions and promoting sustainability. However, specific reduction targets or achievements for Janssen Biotech are not detailed in the available data. While no absolute emissions figures are provided, the commitment to sustainability and climate action is evident through the initiatives cascaded from Johnson & Johnson. The company is aligned with industry standards for climate action, focusing on reducing its carbon footprint and contributing to broader environmental goals.
Access structured emissions data, company-specific emission factors, and source documents
1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Janssen Biotech, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.